

Disclosure Purpose: 21-19641

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Plasma Neutralization Properties of the SARS-CoV-2 Omicron Variant
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19641

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|---|------------|---|
| Pfizer | Consultant | Self |
| <i>Category:</i> Consultant <i>Additional Information:</i> 3 hours, \$400/hour | | <i>Description:</i> Occasional consulting on COVID vaccines |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Plasma neutralization properties of the SARS-CoV-2 Omicron variant
- Are you the corresponding author?**
Yes.
 - Please list the other authors' names here.**
Fabian Schmidt, Frauke Muecksch, Yiska Weisblum, Justin Da Silva, Eva Bednarski, Alice Cho, Zijun Wang, Christian Gaebler, Marina Caskey, Michel C. Nussenzweig, Theodora Hatzioannou

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19641

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Plasma Neutralization Properties of the SARS-CoV-2 Omicron Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19641

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Plasma Neutralization Properties of the SARS-CoV-2 Omicron Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19641

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Plasma Neutralization Properties of the SARS-CoV-2 Omicron Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19641

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Plasma Neutralization Properties of the SARS-CoV-2 Omicron Variant
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19641

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Plasma neutralization properties of the SARS-CoV-2 Omicron Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19641

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Plasma neutralization properties of the SARS-CoV-2 Omicron variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19641

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|--|-------|---|
| Celldex Therapeutics | Other | Self |
| <i>Category:</i> Other <i>Additional Information:</i> | | <i>Description:</i> Scientific Advisory Board |
| Frontier Biotechnologies | Other | Self |
| <i>Category:</i> Other <i>Additional Information:</i> | | <i>Description:</i> Scientific Advisory Board |
| Walking Fish Therapeutics | Other | Self |
| <i>Category:</i> Other <i>Additional Information:</i> | | <i>Description:</i> Scientific Advisory Board |

Intellectual Property

| Type | Is Licensed | Interest Held By | | | | | | |
|---|--|--|------|-----------------|--|--|--|--|
| Other Intellectual Property - Royalties for HIV antibodies | Yes | Self | | | | | | |
| <i>Description:</i> Royalties for HIV antibodies <i>Licensees:</i> | | <i>Type:</i> <i>Additional Information:</i> | | | | | | |
| <table border="1"> <thead> <tr> <th>Licensee</th> <th>Title</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>Gilead Sciences</td> <td>Human Immunodeficiency Virus Neutralizing Antibodi</td> <td></td> </tr> </tbody> </table> | Licensee | Title | Date | Gilead Sciences | Human Immunodeficiency Virus Neutralizing Antibodi | | | |
| Licensee | Title | Date | | | | | | |
| Gilead Sciences | Human Immunodeficiency Virus Neutralizing Antibodi | | | | | | | |
| Patent - Neutralizing anti-SARS-CoV2 antibodies and metho ... | No | Self | | | | | | |
| <i>Description:</i> Neutralizing anti-SARS-CoV2 antibodies and methods of use thereof <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> <i>Licensees:</i> | | <i>Patent Number:</i> PCT/US2021/070472 <i>Patent Holder:</i> <i>Additional Information:</i> | | | | | | |
| Patent - Broadly-Neutralizing Anti-HIV Antibodies | No | Self | | | | | | |
| <i>Description:</i> Broadly-Neutralizing Anti-HIV Antibodies <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> <i>Licensees:</i> | | <i>Patent Number:</i> US2013/065696 <i>Patent Holder:</i> Current Institution <i>Additional Information:</i> | | | | | | |
| Patent - Human Immunodeficiency Virus Neutralizing Antibo ... | No | Self | | | | | | |
| <i>Description:</i> Human Immunodeficiency Virus Neutralizing Antibodies and Methods of Use Thereof <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> USA <i>Licensees:</i> | | <i>Patent Number:</i> PCT/US2012/038400 <i>Patent Holder:</i> Current Institution <i>Additional Information:</i> | | | | | | |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Plasma neutralization properties of the SARS-CoV-2 Omicron variant
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19641

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Plasma Neutralization Properties of the SARS-CoV-2 Omicron Variant
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19641

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Plasma Neutralization Properties of the SARS-CoV-2 Omicron Variant
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19641

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Plasma Neutralization Properties of the SARS-CoV-2 Omicron Variant
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

